Skip to search formSkip to main contentSkip to account menu

eluxadoline

Known as: 5-({(4-carbamoyl-2,6-dimethyl-L-phenylalanyl)[(1S)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino}methyl)-2-methoxybenzoic acid 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (3)

Gastrointestinal AgentsImidazolesPhenylalanine
analogs & derivativeseluxadoline 75 MG Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Preparation, Evaluation and Bioavailability Studies of Eudragit Coated PLGA Nanoparticles for Sustained Release of Eluxadoline for the Treatment of Irritable Bowel Syndrome
Eluxadoline is a newly approved orally administered drug used for the treatment of Irritable Bowel Syndrome with Diarrhea. It is… 
2017
2017
Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
The mixed μ‐ and κ‐opioid receptor agonist and δ‐opioid receptor antagonist, eluxadoline, is licensed in the USA for the… 
Review
2017
Review
2017
Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome
Eluxadoline (Truberzi®) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a… 
Review
2017
Review
2017
New therapeutic options for IBS: the role of the first in class mixed µ- opioid receptor agonist and δ-opioid receptor antagonist (mudelta) eluxadoline
ABSTRACT Introduction: Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder which represents a… 
2017
2017
Eluxadoline (Viberzi): A Mu-Opioid Receptor Agonist for the Treatment Of Irritable Bowel Syndrome With Diarrhea.
Eluxadoline (Viberzi) for the treatment of irritable bowel syndrome with diarrhea. 
2017
2017
Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
Eluxadoline has emerged as an effective treatment option for patients with diarrhea- predominant irritable bowel syndrome (IBS-D… 
Review
2016
Review
2016
Rifaximin and eluxadoline — newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?
ABSTRACT Introduction: Diarrhea-predominant irritable bowel syndrome (IBS-D) is a common functional gastrointestinal condition in… 
2016
2016
Eluxadoline: a promising therapy that raises many questions.
In the United States (US) there are three medications currently approved for the treatment of irritable bowel syndrome (IBS)-D… 
Review
2015
Review
2015
Eluxadoline: First Global Approval
Eluxadoline (Viberzi™), developed by Actavis (now Allergan), is an orally administered, first-in-class compound that functions as… 
2015
2015
Su1386 Clinical Benefit and Intestinal Mucosal Transcriptome Modulation After Long-Term Mast Cell Stabilization With Oral Disodium Cromoglycate in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)